الأربعاء 13 ربيع الأول 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd) | Novartis | Completed | Nilotinib | 3b | CAMN107E2401 | King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital and Oncology Center (Jeddah) |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) | AstraZeneca | Ongoing | Tezepelumab | 3 | D5180C00018 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| Comparison of the Efficacy and Safety for different regimen of Venous Thromboembolism pharmacoprophylaxis among Severely Burn Patients: A Multicenter, Randomized Controlled Trial | KAIMRC | Ongoing | HEPARIN SODIUM, ENOXAPARIN SODIUM | 4 | RC18/400/R | King Abdulaziz Medical City NG (Riyadh) |
| Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma | SANOFI | Ongoing | DUPILUMAB | 4 | LPS15834 | King Fahad Medical City (Riyadh) |
| Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis | Eli Lilly | Ongoing | Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care | 4 | 1F-MC-B007 | Hira Hospital (Makkah) |
| Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) | Abbvie | Ongoing | Drug choice as per treating physician which is not limited per the protocol | 4 | H19-940 | Hira Hospital (Makkah), Security Force Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Sanofi | Ongoing | DUPILUMAB | 4 | OBS15990 | King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| "A Multinational, Prospective, Observational Study of theEffectiveness, Healthcare Resource Utilization and Costsin Patients with Rheumatoid Arthritis ReceivingBaricitinib, Targeted Synthetic or BiologicDisease-Modifying Therapies" | Eli Lilly | Ongoing | Baricitinib | 4 | I4V-MCB009 | Specialized Medical Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Takhassusi (Riyadh) |
| Guidelines Oriented Approach to Lipid lowering Quality Enhancement Research Initiative (GOAL QuERI) International | Canadian Heart Research Centre | Ongoing | any SFDA registered anti-hyperlipidemic product | 4 | CHRC2019 | King Fahd Armed Forces Hospital (Jeddah), King Fahd Military Medical Complex (Dhahran), King Abdullah Medical Complex (Jeddah), King Fahad Hospital (Jeddah), King Fahad Genaral Hospital (Medina), King Khaled General Hospital (Hafar Al Batin), Royal Commission Hospital Jubail |
| A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with Type 2 diabetes mellitus, treated with iGlarLixi fixed ratio combination (SOLIQUA®) before, during and after the period of Ramadan (SoliRam Study) | Sanofi | Ongoing | Soliqua® Solostar | 4 | OBS16049 | University District Hospital (Jeddah), Alzafer Hospital (Najran), Ghassan Najeeb Pharaon hospital (Jeddah) |
تاريخ آخر تحديث: 10/09/2026 بتمام الساعة 10:01 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.